arrow
K

Katherine E. Hutchinson

Vanderbilt University
H指数:30
被引数:4,621

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions

entrectinib在颅外实体或中枢神经系统 (CNS) 肿瘤携带NTRK或ROS1融合的儿童中的疗效和安全性

2025-02-010
OAAI
EFFICACY AND SAFETY OF ENTRECTINIB IN CHILDREN WITHNTRK ORROS1 FUSION-POSITIVE (FP) PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
2024-06-180
OAAI
Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study
2022-06-1726
OAAI
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
2022-04-0856
OAAI
A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer
2022-02-153
PRE
PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2-BC)

激素受体阳性/HER2-negative乳腺癌GDC-0077的I/Ib期研究中的PI3K通路生物标志物和临床反应 (HR /HER2-BC)

2020-09-010
OAAI
Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)

PIK3CA-mutant/激素受体阳性/HER2-negative局部晚期或转移性乳腺癌 (HR /HER2-LA/MBC) 患者 (pts) 的GDC-0077或安慰剂 (pbo) 联合palbociclib (P) 加氟维司群 (F) 的III期研究

2020-09-016
OAAI
CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional Mechanisms
2019-08-0130
OAAI
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer (vol 77, pg 2488, 2017)
2019-02-151
PREAI
ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors
2018-05-3129
OAAI
Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance
2017-08-0990
OAAI
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+Breast Cancers With ERBB Ligand Overexpression
2017-06-0331
OAAI